General Information |
| Summary |
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2020-03-19 |
| End date (estimated) |
2023-03-29 |
| Clinical feature |
| Label |
chronic lymphocytic leukemia |
| Link |
http://purl.obolibrary.org/obo/DOID_1040 |
| Description |
A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.; Xref MGI. |
|
Administrative Information |
| NCT number |
NCT04245722 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04245722 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT04245722 |
| Public contact |
| Email |
clinical@fatetherapeutics.com |
| Public email |
clinical@fatetherapeutics.com |
| First name |
Rebecca |
| Last name |
Reynolds |
| Phone |
+1 (0)858-875-1800 |
| Country |
|
|
| Sponsors |
Fate Therapeutics
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Terminated |
| Estimated number of participants |
98 |
